Glow Lifetech Reports Fourth Quarter and Full Year 2025 Financial Results; 146% YoY Revenue Growth and Second Consecutive Quarter of Positive Cash Flow

• Earnings release (04‑08‑2026) reports FY 2025 revenue of $2.05 M (+146% YoY) and gross profit of $1.36 M (+130%).
• Gross margin remains high at 66%, albeit down from 71% a year earlier.
• The company achieved debt‑free status in Nov 2025 and posted a second consecutive quarter of positive operating cash flow (Q4 2025 CFO $105,866).
• Management forecasts continued revenue and EBITDA growth in 2026 driven by national retail expansion (Ontario, New Brunswick, Saskatchewan, Manitoba) and entry into the medical‑cannabis channel via Mendo.
• Significant capital‑structure cleanup: Q1 2026 warrant/option reductions removed ~41 M warrants and 5 M options; $542k raised from exercised warrants (mostly insiders). Fully‑diluted share count down ~16.6% YoY.

The earnings beat, debt elimination and aggressive over‑hang reduction are materially positive for a micro‑cap with limited cash runway.
- Revenue surge validates the national rollout strategy and suggests market acceptance of MOD™ and .decimal™ brands.
- Debt‑free balance sheet removes interest expense and frees cash for growth, lowering financial risk dramatically.
- Warrant/option cleanup improves equity quality, reduces dilution risk, and signals confidence from insiders (≈89% exercised by management & long‑term shareholders).
Overall, the news exceeds prior expectations (previous releases hinted at positive cash flow but not a full debt wipe‑out plus such revenue magnitude), making it material‑positive rather than routine.

Glow Lifetech develops and markets cannabis‑derived nutraceuticals, focusing on high‑margin oil products under the MOD™ and .decimal™ brands. The flagship SKU is MOD™ THC 1000 oil, currently #2 in Ontario’s oils category. Recent expansion includes a medical‑cannabis channel (Mendo) and national retail rollout across four provinces.